Double hit lymphoma: the <scp>MD A</scp> nderson <scp>C</scp> ancer <scp>C</scp> enter clinical experienceYasuhiro Oki, Jason R. Westin, Fredrick B. Hagemeister et al.|British Journal of Haematology|2014Cited by 364
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trialNathan Fowler, Sattva S. Neelapu, R. Eric Davis et al.|The Lancet Oncology|2014Cited by 263
Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell TransplantationAlex F. Herrera, Philippe Armand, Matthew Mei et al.|Journal of Clinical Oncology|2016Cited by 187
Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell LymphomaAlex F. Herrera, Matthew J. Matasar, Lu Chen et al.|Blood|2022Cited by 18